Ex vivo keratinocyte gene therapy (Netherton syndrome), UCL

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEx vivo keratinocyte gene therapy (Netherton syndrome), UCL
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy
Mechanisms of ActionSPINK5 gene stimulantsKeratinocytes modulators
TargetsSerine protease inhibitor Kazal-type 5
Therapy Area/IndicationsNetherton Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of London
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of London
Inactive CompaniesN/A
Active IndicationsNetherton Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A